Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

“Opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED): Controlled Randomized Study, will be presented by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.”

The abstract, entitled "Opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED): Controlled Randomized Study, will be presented by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

Dr. Roger Crystal, Chief Executive Officer of Lightlake, commented, "We are pleased that our Phase II study was accepted by this most prestigious medical organization. We believe intranasal naloxone is a truly differentiated treatment for BED, one of the major causes of obesity and the most chronic and common of all eating disorders, because it extinguishes the harmful eating behavior."